Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Share-based Compensation (2021 - 2025)

Krystal Biotech's Share-based Compensation history spans 5 years, with the latest figure at $13.8 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 3.05% year-over-year to $13.8 million; the TTM value through Dec 2025 reached $54.5 million, up 10.97%, while the annual FY2025 figure was $54.5 million, 10.97% up from the prior year.
  • Share-based Compensation for Q4 2025 was $13.8 million at Krystal Biotech, up from $13.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $14.1 million in Q2 2025 and bottomed at $2.3 million in Q1 2021.
  • The 5-year median for Share-based Compensation is $9.7 million (2022), against an average of $9.6 million.
  • The largest annual shift saw Share-based Compensation soared 177.99% in 2022 before it fell 10.9% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $5.1 million in 2021, then soared by 85.66% to $9.6 million in 2022, then grew by 3.15% to $9.9 million in 2023, then surged by 35.55% to $13.4 million in 2024, then grew by 3.05% to $13.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Share-based Compensation are $13.8 million (Q4 2025), $13.2 million (Q3 2025), and $14.1 million (Q2 2025).